Post by Michael Kocher
Securing access to last-line-of-defense antibiotics now and for generations to come as President & CEO of Xellia Pharmaceuticals
Did you know I was a chemist by training? 👨🔬 Visiting our R&D labs in Oslo felt like a walk down memory lane, back to my academic roots and a flashback on why I was captivated by science in the first place. One thing I've always admired about scientists is their resilience. Experiments fail. Hypotheses prove wrong. Progress rarely happens in a straight line. Yet scientists keep going. When something doesn’t work, you go back, rethink, and try again. Breakthroughs are rare. Progress comes from refusing to give up. That mindset doesn’t leave you, no matter where your career takes you. Oslo is also where the Xellia story began in 1903. For more than a century, curiosity, persistence, and innovation have been at the heart of what we do. Today, our team continues that legacy every day by improving strains, optimizing purity profiles, and refining processes to reduce uncertainty and deliver the high-quality anti-infective medicines that patients depend on. The pioneering spirit that shaped Xellia Pharmaceuticals 123 years ago is still very much alive. Walking those labs again, I was reminded that the best science isn’t just about what you know. It’s about insisting that tomorrow's solutions are still waiting to be discovered 🔬
Video Content